Author:
Texidor Williams Monier,Miller Matthew A.,Molina Kyle C.,Krsak Martin,Calvert Barbara,Hart Caitlin,Storer Marie,Fish Douglas N.
Abstract
Abstract
Background
Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms. We aimed to assess the effectiveness and safety of oritavancin for consolidative treatment of Gram-positive bloodstream infections (BSI), including infective endocarditis (IE).
Methods
We conducted a retrospective cohort study evaluating adult patients admitted to University of Colorado Hospital from March 2016 to January 2022 who received ≥ 1 oritavancin dose for treatment of Gram-positive BSI. Patients were excluded if the index culture was drawn at an outside facility or were > 89 years of age. The primary outcome was a 90-day composite failure (clinical or microbiological failure) in those with 90-day follow-up. Secondary outcomes included individual components of the primary outcome, acute kidney injury (AKI), infusion-related reactions (IRR), and institutional cost avoidance.
Results
Overall, 72 patients were included. Mean ± SD age was 54 ± 16 years, 61% were male, and 10% had IE. Organisms most commonly causing BSI were Staphylococcus aureus (68%, 17% methicillin-resistant), followed by Streptococcus spp. (26%), and Enterococcus spp. (10%). Patients received standard-of-care antibiotics before oritavancin for a median (IQR) of 11 (5–17) days. Composite failure in the clinically evaluable population (n = 64) at 90-days occurred in 14% and was composed of clinical and microbiological failure, which occurred in 14% and 5% of patients, respectively. Three patients (4%) experienced AKI after oritavancin, and two (3%) experienced an IRR. Oritavancin utilization resulted in earlier discharge for 94% of patients corresponding to an institutional cost-avoidance of $3,055,804 (mean $44,938/patient) from 1,102 hospital days saved (mean 16 days/patient).
Conclusions
The use of oritavancin may be an effective sequential therapy for Gram-positive BSI to facilitate early discharge resulting in institutional cost avoidance.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of Methicillin-Resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.
2. Rentala M, Andrews S, Tiberio A, Alagappan K, Tavdy T, Sheppard P, et al. Intravenous home infusion therapy instituted from a 24-Hour clinical decision unit for patients with Cellulitis. Am J Emerg Med. 2016;34:1273–5.
3. Jaffa RK, Pillinger KE, Roshdy D, Isip JA, Pasquale TR. Novel developments in the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2019;20:1493–502.
4. Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the management of outpatient parenteral antimicrobial therapya. Clin Infect Dis. 2019;68:e1–35.
5. Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, et al. Use of Oritavancin in Moderate-to-severe ABSSSI patients requiring IV antibiotics: a U.S. Payer Budget Impact Analysis. J Manag Care Spec Pharm. 2016;22:752–64.